The present specification relates to the use of combinations comprising 1-(4-(5-(5- amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3- yl)piperidin-1-yl)-3-hydroxypropan-1-one (Compound [I]) or a pharmaceutically acceptable salt thereof, and either a cyclin-dependent kinase (CDK) inhibitor or an anti- estrogen agent, or both a CDK inhibitor and an anti-estrogen agent, in the treatment or prophylaxis of cancer pharmaceutical compositions comprising Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti- estrogen agent kits comprising Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti-estrogen agent, optionally with instructions for use methods of treatment comprising the simultaneous, sequential or separate administration of Compound [I] or a pharmaceutically acceptable salt thereof and either or both of a CDK inhibitor and an anti-estrogen agent, to a warm-blooded animal, such as man and the intermittent dosing of Compound [I] or a pharmaceutically acceptable salt thereof either alone or in combination with either or both of a CDK inhibitor and an anti-estrogen agent.La présente invention concerne lutilisation de combinaisons comprenant de la 1-(4-(5-(5- amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-éthyl-1H-1,2,4-triazol-3- yl)pipéridin-1-yl)-3-hydroxypropan-1-one (composé [I]) ou un sel pharmaceutiquement acceptable de celle-ci, et soit un inhibiteur de kinases cycline-dépendantes (CDK) ou un agent anti-œstrogène, soit à la fois un inhibiteur des CDK et un agent anti-œstrogène, dans le traitement ou la prophylaxie du cancer des compositions pharmaceutiques comprenant le composé [I] ou un sel pharmaceutiquement acceptable de celui-ci et lun ou lautre ou les deux dun inhibiteur des CDK et dun agent anti-œstrogène des kit comprenant le composé [I] ou un sel pharmaceutiquement acceptable de celui-ci et lun ou
